Key statistics
On Monday, Immunic Inc (IMUX:NSQ) closed at 1.60, -24.17% below its 52-week high of 2.11, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.88 |
---|---|
High | 1.89 |
Low | 1.59 |
Bid | 1.56 |
Offer | 1.69 |
Previous close | 1.83 |
Average volume | 954.97k |
---|---|
Shares outstanding | 90.08m |
Free float | 83.12m |
P/E (TTM) | -- |
Market cap | 164.84m USD |
EPS (TTM) | -1.51 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
- EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
- EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
- EQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- EQS-News: Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
- EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
More ▼